TLS, EWS and TAF15: A model for transcriptional integration of gene expression

Briefings in Functional Genomics and Proteomics

Volumn 5, Issue 1, 2006, Pages 8-14

  Law, Warren J ^a   Cann, Kendra L ^a   Hicks, Geoffrey G ^a  

^a UNIVERSITY OF MANITOBA   (Canada)

Author keywords

Cancer; EWS; TAF15; TLS; Transcription; YB 1

Indexed keywords

HEAT SHOCK PROTEIN; HYBRID PROTEIN; MESSENGER RNA; PROTEIN TAF15; PROTEIN TLS; RNA BINDING PROTEIN; RNA BINDING PROTEIN EWS; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG; Y BOX BINDING PROTEIN 1; ONCOPROTEIN; TAF15 PROTEIN, HUMAN; TATA BINDING PROTEIN ASSOCIATED FACTOR;

ARTICLE; CARCINOGENESIS; FUSION GENE; GENE EXPRESSION; GENE TARGETING; HUMAN; MALIGNANT NEOPLASTIC DISEASE; MOLECULAR MODEL; NONHUMAN; PROTEIN DOMAIN; PROTEIN FAMILY; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; RNA SPLICING; RNA TRANSPORT; TRANSCRIPTION INITIATION; WILD TYPE; CHEMISTRY; GENETIC TRANSCRIPTION; GENETICS; METABOLISM; NEOPLASM; PROTEIN TERTIARY STRUCTURE; REVIEW;

GENE EXPRESSION; HUMANS; NEOPLASMS; ONCOGENE PROTEINS, FUSION; PROTEIN STRUCTURE, TERTIARY; RNA-BINDING PROTEIN EWS; RNA-BINDING PROTEIN FUS; TATA-BINDING PROTEIN ASSOCIATED FACTORS; TRANSCRIPTION FACTORS; TRANSCRIPTION, GENETIC;

EID: 33745945163     PISSN: 14739550     EISSN: 14774062     Source Type: Journal    
DOI: 10.1093/bfgp/ell015     Document Type: Article

References (66)

1. Bertolotti A, Lutz Y, Heard DJ, et al. hTAF(II)68, a novel RNA/ ssDNA-binding protein with homology to the pro-oncoproteins TLS/FUS and EWS is associated with both TFIID and RNA polymerase II. EMBO J 1996;15:5022-31.
2. Morohoshi F, Ootsuka Y, Arai K, et al. Genomic structure of the human RBP56/hTAFII68 and FUS/TLS genes. Gene 1998;221:191-8.
3. Crozat A, Aman P, Mandahl N, et al. Fusion of CHOP to a novel RNA-binding protein in human myxoid liposarcoma. Nature 1993;363:640-4.
4. Rabbitts TH, Forster A, Larson R, et al. Fusion of the dominant negative transcription regulator CHOP with a novel gene FUS by translocation t (12;16) in malignant liposarcoma. Nat Genet 1993;4:175-80.
5. Delattre O, Zucman J, Plougastel B, et al. Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours. Nature 1992;359:162-5.
6. Prasad DD, Ouchida M, Lee L, et al. TLS/FUS fusion domain of TLS/FUS-erg chimeric protein resulting from the t (16;21) chromosomal translocation in human myeloid leukemia functions as a transcriptional activation domain. Oncogene 1994;9:3717-29.
7. May WA, Lessnick SL, Braun BS, et al. The Ewing's sarcoma EWS/FLI-1 fusion gene encodes a more potent transcriptional activator and is a more powerful transforming gene than FLI-1. Mol Cell Biol 1993;13:7393-8.
8. Bertolotti A, Bell B, Tora L. The N-terminal domain of human TAFII68 displays transactivation and oncogenic properties. Oncogene 1999;18:8000-10.
9. Antonescu CR, Elahi A, Humphrey M, et al. Specificity of TLS-CHOP rearrangement for classic myxoid/round cell liposarcoma: Absence in predominantly myxoid well-differentiated liposarcomas. J Mol Diagn 2000;2:132-8.
10. Sorensen PH, Lessnick SL, Lopez-Terrada D, et al. A second Ewing's sarcoma translocation, t (21;22), fuses the EWS gene to another ETS-family transcription factor, ERG. Nat Genet 1994;6:146-51.
11. Perez-Losada J, Pintado B, Gutierrez-Adan A, et al. The chimeric FUS/ TLS-CHOP fusion protein specifically induces liposarcomas in transgenic mice. Oncogene 2000;19:2413-22.
12. Perez-Losada J, Sanchez-Martin M, Rodriguez-Garcia MA, et al. Liposarcoma initiated by FUS/TLS-CHOP: The FUS/TLS domain plays a critical role in the pathogenesis of liposarcoma. Oncogene 2000;19:6015-22.
13. Perez-Mancera PA, Perez-Losada J, Sanchez-Martin M, et al. Expression of the FUS domain restores liposarcoma development in CHOP transgenic mice. Oncogene 2002;21: 1679-84.
14. Perrotti D, Bonatti S, Trotta R, et al. TLS/FUS, a pro-oncogene involved in multiple chromosomal translocations, is a novel regulator of BCR/ ABL-mediated leukemogenesis. EMBO J 1998;17:4442-55.
15. Ohno T, Ouchida M, Lee L, et al. The EWS gene, involved in Ewing family of tumors, malignant melanoma of soft parts and desmoplastic small round cell tumors, codes for an RNA binding protein with novel regulatory domains. Oncogene 1994;9:3087-97.
16. Cassiday LA, Maher LJ, 3rd. Having it both ways: Transcription factors that bind DNA and RNA. Nucleic Acids Res 2002;30:4118-26.
17. Yang L, Embree LJ, Tsai S, et al. Oncoprotein TLS interacts with serine-arginine proteins involved in RNA splicing. J Biol Chem 1998;273:27761-6.
18. Zinszner H, Sok J, Immanuel D, et al. TLS (FUS) binds RNA in vivo and engages in nucleo-cytoplasmic shuttling. J Cell Sci 1997;110:1741-50.
19. Fuji R, Okabe S, Urushido T, et al. The RNA binding protein TLS is translocated to dendritic spines by mGluR5 activation and regulates spine morphology. Curr Biol 2005; 15:587-93.
20. Zinszner H, Albalat R, Ron D. A novel effector domain from the RNA-binding protein TLS or EWS is required for oncogenic transformation by CHOP. Genes Dev 1994;8: 2513-26.
21. Bertolotti A, Melot T, Acker J, et al. EWS, but not EWS-FLI-1, is associated with both TFIID and RNA polymerase II: Interactions between two members of the TET family, EWS and hTAFII68, and subunits of TFIID and RNA polymerase II complexes. Mol Cell Biol 1998;18: 1489-97.
22. Yang L, Embree LJ, Hickstein DD. TLS-ERG leukemia fusion protein inhibits RNA splicing mediated by serine-arginine proteins. Mol Cell Biol 2000;20:3345-54.
23. Powers CA, Mathur M, Raaka BM, et al. TLS (translocated-in-liposarcoma) is a high-affinity interactor for steroid, thyroid hormone, and retinoid receptors. Mol Endocrinol 1998;12:4-18.
24. Hallier M, Lerga A, Barnache S, et al. The transcription factor Spi-1/ PU.1 interacts with the potential splicing factor TLS. J Biol Chem 1998;273:4838-42.
25. Uranishi H, Tetsuka T, Yamashita M, et al. Involvement of the pro-oncoprotein TLS (translocated in liposarcoma) in nuclear factor-kappa B p65-mediated transcription as a coactivator. J Biol Chem 2001;276:13395-401.
26. Scott EW, Simon MC, Anastasi J, et al. Requirement of transcription factor PU.1 in the development of multiple hematopoietic lineages. Science 1994;265:1573-7.
27. Moreau-Gachelin F, Tavitian A, Tambourin P. Spi-1 is a putative oncogene in virally induced murine erythro-leukaemias. Nature 1988;331:277-80.
28. McKercher SR, Torbett BE, Anderson KL, et al. Targeted disruption of the PU.1 gene results in multiple hematopoietic abnormalities. Embo J 1996;15:5647-58.
29. Kucharczak J, Simmons MJ, Fan Y, et al. To be, or not to be: NF-kappaB is the answer-role of Rel/NF-kappaB in the regulation of apoptosis. Oncogene 2003;22:8961-82.
30. Barkett M, Gilmore TD. Control of apoptosis by Rel/NFkappaB transcription factors. Oncogene 1999;18:6910-24.
31. Gascoyne DM, Thomas GR, Latchman DS. The effects of Brn-3a on neuronal differentiation and apoptosis are differentially modulated by EWS and its oncogenic derivative EWS/Fli-1. Oncogene 2004;23:3830-40.
32. Thomas GR, Latchman DS. The pro-oncoprotein EWS (Ewing's Sarcoma protein) interacts with the Brn-3a POU transcription factor and inhibits its ability to activate transcription. Cancer Biol Ther 2002;1:428-32.
33. Thomas GR, Faulkes DJ, Gascoyne D, et al. EWS differentially activates transcription of the Brn-3a long and short isoform mRNAs from distinct promoters. Biochem Biophys Res Commun 2004;318:1045-51.
34. Rossow KL, Janknecht R. The Ewing's sarcoma gene product functions as a transcriptional activator. Cancer Res 2001;61:2690-5.
35. Zhang D, Paley AJ, Childs G. The transcriptional repressor ZFM1 interacts with and modulates the ability of EWS to activate transcription. J Biol Chem 1998;273: 18086-91.
36. Hicks GG, Singh N, Nashabi A, et al. Fus deficiency in mice results in defective B-lymphocyte development and activation, high levels of chromosomal instability and perinatal death. Nat Genet 2000;24:175-9.
37. Kohno K, Izumi H, Uchiumi T, et al. The pleiotropic functions of the Y-box-binding protein, YB-1. Bioessays 2003;25:691-8.
38. Chansky HA, Hu M, Hickstein DD, et al. Oncogenic TLS/ERG and EWS/Fli-1 fusion proteins inhibit RNA splicing mediated by YB-1 protein. Cancer Res 2001;61:3586-90.
39. Ohga T, Koike K, Ono M, et al. Role of the human Y box-binding protein YB-1 in cellular sensitivity to the DNA-damaging agents cisplatin, mitomycin C, and ultraviolet light. Cancer Res 1996;56:4224-8.
40. Koike K, Uchiumi T, Ohga T, et al. Nuclear translocation of the Y-box binding protein by ultraviolet irradiation. FEBS Lett 1997;417:390-4.
41. Mertens PR, Alfonso-Jaume MA, Steinmann K, et al. A synergistic interaction of transcription factors AP2 and YB-1 regulates gelatinase A enhancer-dependent transcription. J Biol Chem 1998;273:32957-65.
42. Uchiumi T, Kohno K, Tanimura H, et al. Enhanced expression of the human multidrug resistance 1 gene in response to UV light irradiation. Cell Growth Differ 1993;4:147-57.
43. Goldsmith ME, Madden MJ, Morrow CS, et al. A Y-box consensus sequence is required for basal expression of the human multidrug resistance (mdr1) gene. J Biol Chem 1993; 268:5856-60.
44. Mertens PR, Harendza S, Pollock AS, et al. Glomerular mesangial cell-specific transactivation of matrix metalloproteinase 2 transcription is mediated by YB-1. J Biol Chem 1997;272:22905-12.
45. Kohno K. Molecular mechanism of the stress induction of MDR1 gene. Nippon Rinsho 1997;55:1054-8.
46. Bargou RC, Jurchott K, Wagener C, et al. Nuclear localization and increased levels of transcription factor YB-1 in primary human breast cancers are associated with intrinsic MDR1 gene expression. Nat Med 1997;3: 447-50.
47. Ichikawa H, Shimizu K, Hayashi Y, Ohki M. An RNA-binding protein gene, TLS/FUS, is fused to ERG in human myeloid leukemia with t(16;21) chromosomal translocation. Cancer Res 1994;54:2865-8.
48. Panagopoulos I, Aman P, Fioretos T, et al. Fusion of the FUS gene with ERG in acute myeloid leukemia with t(16;21)(p11;q22). Genes Chromosomes Cancer 1994;11: 256-62.
49. Waters BL, Panagopoulos I, Allen EF. Genetic characterization of angiomatoid fibrous histiocytoma identifies fusion of the FUS and ATF-1 genes induced by a chromosomal translocation involving bands 12q13 and 16p11. Cancer Genet Cytogenet 2000;121:109-16.
50. Storlazzi CT, Mertens F, Nascimento A, et al. Fusion of the FUS and BBF2H7 genes in low grade fibromyxoid sarcoma. Hum Mol Genet 2003;12:2349-58.
51. Shing DC, McMullan DJ, Roberts P, et al. FUS/ERG gene fusions in Ewing's tumors. Cancer Res 2003;63:4568-76.
52. Zucman J, Melot T, Desmaze C, et al. Combinatorial generation of variable fusion proteins in the Ewing family of tumours. Embo J 1993;12:4481-7.
53. Jeon IS, Davis JN, Braun BS, et al. A variant Ewing's sarcoma translocation (7;22) fuses the EWS gene to the ETS gene ETV1. Oncogene 1995;10:1229-34.
54. Kaneko Y, Yoshida K, Handa M, et al. Fusion of an ETS-family gene, EIAF, to EWS by t(17;22)(q12;q12) chromosome translocation in an undifferentiated sarcoma of infancy. Genes Chromosomes Cancer 1996;15:115-21.
55. Urano F, Umezawa A, Hong W, et al. A novel chimera gene between EWS and E1A-F, encoding the adenovirus E1A enhancer-binding protein, in extraosseous Ewing's sarcoma. Biochem Biophys Res Commun 1996;219:608-12.
56. Peter M, Couturier J, Pacquement H, et al. A new member of the ETS family fused to EWS in Ewing tumors. Oncogene 1997;14:1159-64.
57. Panagopoulos I, Hoglund M, Mertens F, et al. Fusion of the EWS and CHOP genes in myxoid liposarcoma. 1996;12:489-94.
58. Zucman J, Delattre O, Desmaze C, et al. EWS and ATF-1 gene fusion induced by t(12;22) translocation in malignant melanoma of soft parts. Nat Genet 1993;4:341-5.
59. Ladanyi M, Gerald W. Fusion of the EWS and WT1 genes in the desmoplastic small round cell tumor. Cancer Res 1994; 54:2837-40.
60. Rauscher FJ, 3rd, Benjamin LE, Fredericks WJ, et al. Novel oncogenic mutations in the WT1 Wilms' tumor suppressor gene: A t(11;22) fuses the Ewing's sarcoma gene, EWS1, to WT1 in desmoplastic small round cell tumor. Cold Spring Harb Symp Quant Biol 1994;59:137-46.
61. Mastrangelo T, Modena P, Tornielli S, et al. A novel zinc finger gene is fused to EWS in small round cell tumor. Oncogene 2000;19:3799-804.
62. Yamaguchi S, Yamazaki Y, Ishikawa Y, et al. EWSR1 is fused to POU5F1 in a bone tumor with translocation t(6;22)(p21;q12). Genes Chromosomes Cancer 2005;43: 217-22.
63. Labelle Y, Zucman J, Stenman G, et al. Oncogenic conversion of a novel orphan nuclear receptor by chromosome translocation. Hum Mol Genet 1995;4:2219-26.
64. Martini A, La Starza R, Janssen H, et al. Recurrent rearrangement of the Ewing's sarcoma gene, EWSR1, or its homologue, TAF15, with the transcription factor CIZ/NMP4 in acute leukemia. Cancer Res 2002;62:5408-12.
65. Attwooll C, Tariq M, Harris M, et al. Identification of a novel fusion gene involving hTAFII68 and CHN from a t(9;17)(q22;q11.2) translocation in an extraskeletal myxoid chondrosarcoma. Oncogene 1999;18:7599-601.
66. Sjogren H, Meis-Kindblom J, Kindblom LG, et al. Fusion of the EWS-related gene TAF2N to TEC in extraskeletal myxoid chondrosarcoma. Cancer Res 1999;59:5064-7.